Dr. Romain Micol has been President, co-founder, and Chief Executive Officer of Combined Therapeutics since 2016. Previously, he held several positions across the Institut Mérieux group: ABL Inc (USA), Shantha Biotechnics (India), and Transgene (China and France). Dr. Micol helped to set up the first reference center for primary immunodeficiency in France in 2005. Dr. Micol is an entrepreneur with affiliations to six famous universities (Massachusetts Institute of Technology or MIT in the U.S., LSE in the UK, Paris VI, Paris V, Paris Dauphine in France and Global LBS in the UK). Dr. Micol obtained his Medical Degree (two specializations in Infectious Diseases and Public Health) from Pierre et Marie Curie University, his Ph.D. in Communicable Diseases from Paris Descartes University, his Master of Business Administration from Hult International Business School and his LLM (Corporate Law – Intellectual Property) from the London School and Economics, and his Advanced Management Program from Massachusetts Institute of Technology.